-
.(* ) The FDA has actually authorized off
- Chemomab Rehabs Ltd’s CMMB Investigational New Medication (IND) Application to review CM-101 in a Stage 2 test in grownups with systemic sclerosis (SSc). .
- .
- .
- .(* )The FDA has actually approved CM-101 Orphan Medication classification for SSc and also for main sclerosing cholangitis (PSC), an uncommon liver condition.
- .
- CMMB shares are up 17.95% at $2.31 on the last check Tuesday.
- © 2023 Benzinga.com. Benzinga does not supply financial investment suggestions. All civil liberties booked.
CM-101 is a first-in-class monoclonal antibody created to disrupt crucial organic paths connected with SSc and also various other fibro-inflammatory conditions.
In preclinical researches, CM-101 decreased inflammatory and also fibrotic injury to the lung, skin, and also vasculature– body organ systems usually impacted in SSc clients.
In very early scientific tests, CM-101 was well-tolerated, minimizing fibrogenesis-related biomarkers and also showing anti-inflammatory results in clients with extreme lung swelling, non-alcoholic fatty liver condition (NAFLD), and also non-alcoholic steatohepatitis (NASH).
.(* )The CM-101 Stage 2 springtime test in PSC clients is presently continuous.
Rate Activity:
.
